Clinical Trial Update: Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma [Phase 2]

View source ↗

Summary

Clinical trial update on using SHR-1701 plus famitinib as neoadjuvant therapy with response-guided adjuvant treatment for resectable mucosal melanoma (Phase 2).…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosal Melanoma

Drugs mentioned

• Famitinib (Famitinib)
• SHR-1701

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Melanoma | Phase 2 | Status: NOT_YET_RECRUITING